New GERD drug aims to keep esophagus healed longer
NCT ID NCT07313774
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 27 times
Summary
This phase 3 trial tests whether a new drug, linaprazan glurate, can keep the esophagus healed in people with healed erosive esophagitis from GERD, compared to the standard drug lansoprazole. About 1050 adults who were healed in a prior trial will take either high or low dose linaprazan glurate or lansoprazole daily for up to 52 weeks. The study is double-blind and uses endoscopies to check if healing is maintained.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERD (GASTROESOPHAGEAL REFLUX DISEASE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.